PRDM5 and gastric cancer: Our results showed that aberrant methylation of PRDM5 was associated with its inactivation in multiple tumor cell lines and primary tumors, with the silencing/methylation of PRDM5 in cell lines of gastric cancer (MKN45) and HCC (huH1, Hep3B and HepG2) consistent with previous studies [14], [15].